Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma

Abstract

Thirty-five consecutive patients with follicular lymphoma (FL) receiving SCT at our institution between January 2000 and December 2010 were included in this study. At the time of presentation, 30 (86%) had advanced stage disease and 25 (71%) received three or more chemotherapy regimens prior to transplantation. In all, 12 (34%) patients were in complete response pre-SCT following salvage therapy. At the time of analysis (median follow-up 6 years from diagnosis and 4 years from transplantation), 24 patients were alive with an estimated 5-year OS and PFS of 66.5 and 53%, respectively. OS and PFS in patients receiving auto-SCT (91.7%, 73.3%) were superior compared with patients receiving allo-SCT (53.9%, 43%). Our data support early use of auto-SCT in patients with FL and suggest the need to improve allo-SCT outcome. Integrating novel agents in a combined modality approach may improve long-term outcome in FL.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Khouri IF . Allogeneic stem cell transplantation in follicular lymphoma. Best Pract Res Clin Haematol 2011; 24: 271–277.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant 2008; 14: 236–245.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM et al. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant 2011; 17: 1051–1057.

    Article  PubMed  Google Scholar 

  4. Freedman A . Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol 2011; 86: 768–775.

    Article  CAS  PubMed  Google Scholar 

  5. Barrett AJ, Savani BN . Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661–1672.

    Article  CAS  PubMed  Google Scholar 

  6. de Lavallade H, Mohty M, El-Cheikh J, Cassier PA, Faucher C, Fürst S et al. Reduced-intensity conditioning allogeneic stem cell transplantation for patients with chemoresistant or relapsed follicular lymphoma. Br J Haematol 2006; 135: 408–410.

    Article  PubMed  Google Scholar 

  7. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008; 111: 5530–5536.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Shafey M, Lupichuk SM, Do T, Owen C, Stewart DA . Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment. Bone Marrow Transplant 2011; 46: 962–969.

    Article  CAS  PubMed  Google Scholar 

  9. Freytes CO, Lazarus HM . Second hematopoietic SCT for lymphoma patients who relapse after autotransplantation: another autograft or switch to allograft? Bone Marrow Transplant 2009; 44: 559–569.

    Article  CAS  PubMed  Google Scholar 

  10. Reddy N, Savani BN . Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach. Biol Blood Marrow Transplant 2011; 17: 1265–1272.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17: 1395–1403.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Pinana JL, Martino R, Gayoso J, Sureda A, de la Serna J, Díez-Martín JL et al. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica 2010; 95: 1176–1182.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Abou-Nassar KE, Stevenson KE, Antin JH, McDermott K, Ho VT, Cutler CS et al. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant 2011; 46: 1503–1509.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Buhmann R, Simoes B, Stanglmaier M, Yang T, Faltin M, Bund D et al. Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 2009; 43: 383–397.

    Article  CAS  PubMed  Google Scholar 

  15. Hicks LK, Woods A, Buckstein R, Mangel J, Pennell N, Zhang L et al. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009; 43: 701–708.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by National Center for Research Resources, National Institute of Health (Grant no. 5K-12 CA090625-09, NR)

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N Reddy.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reddy, N., Greer, J., Goodman, S. et al. Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma. Bone Marrow Transplant 47, 1318–1320 (2012). https://doi.org/10.1038/bmt.2012.10

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.10

Keywords

This article is cited by

Search

Quick links